Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions
GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.
Pharma & Biotech
Pharma & Biotech
Why Servier’s $2.5bn acquisition of Day One Biopharmaceuticals could reshape the pediatric glioma treatment landscape
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.